Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
A phase 3 trial of Plitidepsin and Dexamethasone in Multiple myeloma, run by PharmaMar, completed.
Overview
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma is a phase 3 interventional study registered as NCT01102426 by PharmaMar, with 255 participants recorded, started 2010-06 and reaching its primary completion in 2017-11. Interventions recorded: Plitidepsin, Dexamethasone. Conditions recorded: Relapsed/Refractory Multiple Myeloma.
Linked to the drug Plitidepsin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Shares Plitidepsin, PharmaMar, Multiple myeloma and the tag pipeline.
- TrialEfficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Shares Plitidepsin and the tag pipeline.
- TrialStudy of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
Shares PharmaMar and the tag pipeline.
- TrialStudy of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Shares PharmaMar and the tag pipeline.
- TrialA Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialDexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialStudy of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialA Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Shares Dexamethasone, Multiple myeloma and the tag pipeline.